BRD9876

Overview

BRD9876 is the “rigor” inhibitor that locks kinesin-5 (Eg5) in a state with enhanced microtubules (MTs) binding, leading to bundling and stabilization of MTs. BRD9876 interacts with the tyrosine 104 residue that is part of the α4-α6 allosteric binding pocket. BRD9876 specifically targets microtubule-bound Eg5 and selectively inhibits myeloma over CD34 cells. BRD9876 has the potential for multiple myeloma (MM) research.

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pain | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Kinesin | Products > Signaling Pathways > Microtubule/Tubulin

Product Information

• Catalog No.: HY-110208
• CAS No.: 32703-82-5
• Molecular Formula: C16H14N2
• Molecular Weight: 234.30
• Purity: 99.37%
• Storage: Store at room temperature, keep dry and cool. In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.5 mg/mL (10.67 mM); Clear solution
• Availability: In-stock

Source

Original product source